Presentations & Reports

17-Mar-2025

Race Investor Presentation

25-Nov-2024

Race Oncology 2024 Chairs Address and AGM Presentation

30-Oct-2024

13th Australian Microcap Investment Conference presentation

26-Sep-2024

E&P Conference Presentation

18-Sep-2024

HealthInvest 2024 Investor Presentation

12-Jul-2024

Bioshares 18th Biotech Summit Presentation

13-May-2024

RAC Investor Presentation May 2024

27-Nov-2023

Race Oncology 2023 Chair's Address & AGM Presentation

22-Nov-2023

Updated Strategy and Investor Presentation

24-Nov-2022

Race 2022 AGM Presentations

1
2
...
...
...

25-Feb-2025

Appendix 4D & Half-Year Financial Statements

17-Dec-2024

Race Receives $5.25m RD Tax Refund for Financial Year 2024

23-Oct-2024

Annual Report to Shareholders

27-Aug-2024

Race Oncology Annual Report 2024

27-Aug-2024

Appendix 4E & Annual Report

18-Apr-2024

Quarterly Activity Report & Appendix 4C

1-Mar-2024

S&P DJI Announces March 2024 Quarterly Rebalance

28-Feb-2024

Appendix 4D & Half-Year Financial Statements

25-Oct-2023

Annual Report to Shareholders

30-Aug-2023

Appendix 4E & Annual Report

...
...
...

1-May-2025

MST Analyst Report: RC220 Trial - First Patient Dosed

9-Apr-2025

MST Analyst Report: RC220 Phase 1 Trial Update – Patients Enrolled, Sites Expanding

17-Dec-2024

Race Oncology: HREC submission for Phase 1 trial

30-Sep-2024

Protecting the Heart, Fighting the Disease: Bisantrene's Dual Action

28-Jun-2024

RC220 clears key safety hurdle – human clinical trials up next

2-May-2024

New RC220 formulation achieves significant milestone

7-Nov-2023

Phase 2 AML interim data strongly support more studies of bisantrene

24-Oct-2023

1QFY24: Key elements click into place for critical CY24 clinical trials

1-Oct-2022

Race Oncology Pitt Street Research Research Initiation Report October 2022

1

L36, 1 Macquarie Place Sydney NSW 2000
E: info@raceoncology.com T: +61 2 8051 3043
© 2025 Race Oncology | Privacy Policy

Sign up to receive the most recent news and updates